Personalized Medication Management for Multiple Medications Safety

Overseen By Cancer Trial Intake, MD

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: University of Chicago

Disqualifiers: Liver transplant, Kidney transplant, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

1300 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial explores whether genetic testing can help doctors prescribe medications more safely for patients taking multiple drugs. Researchers aim to understand how genes affect medication response, with the goal of reducing side effects and improving treatment. Participants will receive either personalized advice from the Personalized Therapeutics Clinic (PTC) based on drug interactions and genetic information or standard care without genetic insights. This trial suits adults taking at least five medications and receiving treatment at the University of Chicago Medical Center. As an unphased trial, it offers a unique opportunity to contribute to groundbreaking research that could enhance medication safety and effectiveness for many patients.

Will I have to stop taking my current medications?

The trial information does not specify if you need to stop taking your current medications. It seems the study focuses on managing and adjusting your medications based on genetic testing rather than stopping them.

What prior data suggests that the Personalized Therapeutics Clinic is safe for managing multiple medications?

Research has shown that personalized medication management, such as the services offered by the Personalized Therapeutics Clinic (PTC), can reduce the risk of side effects. This approach uses genetic information to guide drug selection. By examining genetic makeup, doctors can make informed decisions about which medications to prescribe and in what amounts.

Studies have found that using genetic data in prescribing can decrease unwanted medication side effects. This method aims to make taking multiple medications safer by preventing harmful interactions between drugs and genes.

The Genomic Prescribing System (GPS) also aids doctors by providing specific genetic information, leading to better prescribing decisions and safer medication use.

Overall, evidence suggests that this personalized approach is well-tolerated and could result in fewer side effects. However, as this is a new method, participating in such a trial may offer more personal insights and benefits. ^{1 2 3 4 5}

Why are researchers excited about this trial?

Researchers are excited about this trial because it explores personalized medication management, aiming to improve safety for patients taking multiple medications. Unlike traditional approaches, which often rely on general prescribing guidelines, this study utilizes detailed drug-drug and drug-gene interaction profiles to tailor treatment plans. One distinctive aspect of this trial is its focus on personalized recommendations, which can lead to more effective and safer medication regimens by addressing specific interactions unique to each patient. By understanding these interactions better, healthcare providers can potentially reduce adverse effects and enhance the therapeutic benefits of medications.

What evidence suggests that the Personalized Therapeutics Clinic (PTC) could be effective for managing multiple medications safely?

Research has shown that personalized medication management can significantly reduce the risk of harmful drug reactions. By examining drug interactions and genetic factors, this method tailors a medication plan to individual genetic profiles. Studies have found that this approach helps doctors make safer prescribing decisions, resulting in fewer side effects. In this trial, participants in Group 1 will receive recommendations based on both drug-drug and drug-gene profiles through the Personalized Therapeutics Clinic (PTC), which uses a Genomic Prescribing System (GPS) to provide specific genetic insights that guide drug choices. Early findings suggest that understanding genetic differences can make taking multiple medications more effective and safer. ^{1 2 3 6 7}

Who Is on the Research Team?

Mark Ratain, MD

Principal Investigator

University of Chicago

Are You a Good Fit for This Trial?

This trial is for adults over 18 at the University of Chicago Medical Center who take 5 or more medications, including those with specific drug interactions or genetic factors affecting medication response. It's not for those with liver/kidney transplants, in other gene studies, or unable to consent.

Inclusion Criteria

Adult participants cared for by a participating provider at University of Chicago Medical Center

I am taking 5 or more medications, including one that requires genetic testing.

Exclusion Criteria

I am being considered for or have had a liver or kidney transplant.

Participation in another pharmacogenomic study

Participants who have previously received genotyping from another source

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Intervention

Participants receive consultations at the Personalized Therapeutics Clinic (PTC) to assess drug-drug and drug-gene interactions and receive recommendations based on their profiles

9 months

Regular educational visits with clinic staff

Follow-up

Participants are monitored for safety and effectiveness after the intervention, including emergency department visits, hospitalizations, and adverse events

9 months

What Are the Treatments Tested in This Trial?

Interventions

• Personalized Therapeutics Clinic (PTC)

Trial Overview

The study tests if a Personalized Therapeutics Clinic (PTC) can reduce side effects by analyzing participants' genes and current medications. The PTC aims to improve prescribing decisions based on drug-drug and drug-gene interactions over a period of roughly 9 months.

How Is the Trial Designed?

Group I: Group 3: Prescribing Not Based on ANY Profile Information (Drug-Drug or Drug-Gene Interactions) Experimental Treatment 1 Intervention

Group three consists of subjects who will not participate in the Personalized Therapeutics Clinic or receive recommendations. These subjects will not have any recommendations from regarding their drug-drug interaction or drug-gene profiles. Both drug-drug interaction and drug-gene profiles will be kept hidden from all of their treating providers-regardless of whether the providers directing their care have agreed to participate in this research. Subjects in this group will not learn about their drug-drug interaction or drug-gene profiles during educational visits with clinic staff. Participants will randomly (like by a flip of the coin) assigned to a group.

Group II: Group 2: Prescribing Based ONLY on Information From Drug-Drug Interaction Profiles Experimental Treatment 1 Intervention

Group two consists of subjects who will participate in the Personalized Therapeutics Clinic where study doctors will make recommendations based on information only found in the subject's drug-drug interaction profile. Subjects in this group will also learn about their drug-drug interaction and drug-gene profiles during educational visits with clinic staff. Participants will randomly (like by a flip of the coin) assigned to a group.

Group III: Group 1: Prescribing Based on Information From Both Drug-Drug and Drug-Gene Profiles Experimental Treatment 2 Interventions

Group one consists of subjects who will participate in the Personalized Therapeutics Clinic where in which study doctors will make recommendations based on information found in both the subject's drug-drug interaction and drug-gene profiles. These recommendations will be given to participating providers. These recommendations will be communicated to healthcare providers who are directing the subject's care. These providers may work in hospitals, primary care, oncology, geriatrics, and mental and behavioral health. Each provider will have separately agreed to participate in this study. Subjects in this group will also learn about their drug-drug interaction and drug-gene profiles during educational visits with clinic staff. Participants will randomly (like by a flip of the coin) assigned to a group.

Who Is Running the Clinical Trial?

University of Chicago

Lead Sponsor

Trials

1,086

Recruited

844,000+

Published Research Related to This Trial

Precision medicine, which uses genetic information to guide drug therapy, can enhance drug efficacy and reduce adverse events, especially in patients taking multiple medications (polypharmacy).

The authors implemented a five-step precision medicine protocol over ten years, demonstrating its effectiveness in tailoring treatments based on individual patient characteristics and pharmacogenetic test results, particularly for those with complex medical histories.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Ten Years of Experience Support Pharmacogenetic Testing to Guide Individualized Drug Therapy. Peña-Martín, MC., García-Berrocal, B., Sánchez-Martín, A., et al.[2022]

Pharmacogenomics (PGx) is changing how medications are prescribed by allowing doctors to tailor drug prescriptions based on individual genetic factors, which can enhance treatment effectiveness and reduce side effects.

In Switzerland, doctors can use validated PGx tests for five specific drugs, indicating a move towards personalized medicine, but this requires proper sharing of PGx data and support for clinicians in making informed prescribing decisions.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

[Pharmacogenomics : a toolbox to improve drug prescription]. Jaccard, E., Redin, C., Girardin, F., et al.[2020]

Adverse drug reactions lead to over 2 million hospitalizations and 100,000 deaths annually in the U.S., highlighting the urgent need for personalized medicine approaches like pharmacogenetics and pharmacogenomics to improve drug safety and efficacy.

Understanding genetic differences in drug metabolism can help tailor treatments to individuals, potentially reducing adverse reactions and improving public health, although challenges such as privacy concerns and the need for education in the clinical community remain significant barriers.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Pharmacogenetics and the concept of individualized medicine. Shastry, BS.[2021]

Pharmacogenomics helps understand how different patients respond to drugs based on their genetic profiles, which can lead to more effective and safer treatments tailored to individual needs.

The review highlights the importance of two types of biomarkers—prognostic and predictive—that can classify patients into subgroups, allowing for personalized treatment recommendations based on their specific responses to therapies.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Pharmacogenomic biomarkers for personalized medicine. Chen, JJ., Lin, WJ., Chen, HC.[2015]

The study developed a protocol to use preemptive pharmacogenomics (PGx) data integrated into electronic medical records (EMR) to guide personalized statin therapy, targeting patients most likely to benefit from this approach.

Out of 2000 participants invited from the Mayo Clinic Biobank, 1013 provided blood samples for PGx testing, which included genotyping and sequencing of relevant genes, indicating a significant interest in personalized medicine and the potential for improved treatment outcomes.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Preemptive genotyping for personalized medicine: design of the right drug, right dose, right time-using genomic data to individualize treatment protocol. Bielinski, SJ., Olson, JE., Pathak, J., et al.[2021]

In a study of 52,942 patients over five years, 64.8% were prescribed at least one medication that could be influenced by genetic variants, highlighting the commonality of pharmacogenetic prescribing opportunities.

Implementing a preemptive genotyping program could potentially prevent 383 adverse events linked to specific medications, suggesting that this approach may enhance patient safety compared to traditional reactive methods.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Optimizing drug outcomes through pharmacogenetics: a case for preemptive genotyping. Schildcrout, JS., Denny, JC., Bowton, E., et al.[2022]

Pharmacogenomics can help predict adverse drug reactions (ADRs) by identifying genetic variations that affect how individuals respond to medications, addressing a significant issue in drug safety.

The review highlights successful examples of pharmacogenomics influencing clinical practice and discusses future areas where it could improve drug safety, while also acknowledging the challenges in implementing these tests in healthcare.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

The emerging era of pharmacogenomics: current successes, future potential, and challenges. Lee, JW., Aminkeng, F., Bhavsar, AP., et al.[2021]

Over 90% of individuals have pharmacogenomic (PGx) variants that can inform medication choices, leading to improved treatment efficacy and reduced adverse drug reactions (ADRs).

The University of Minnesota successfully implemented a PGx testing program that includes a multiplex PCR assay for 20 genes, enhancing the ability of clinicians to use genetic information for personalized medicine through a user-friendly software tool for translating genetic data into actionable treatment recommendations.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Development and Implementation of In-House Pharmacogenomic Testing Program at a Major Academic Health System. Mroz, P., Michel, S., Allen, JD., et al.[2021]

The 1,200 Patients Project successfully implemented preemptive pharmacogenomic testing for 812 patients, achieving a 90% participation rate, which indicates strong patient interest in personalized medicine.

Results from the genomic prescribing system showed that physicians accessed pharmacogenomic information in 86% of visits, with 57% of medications receiving a 'green light' (favorable), demonstrating high physician adoption and relevance of the testing results.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Adoption of a clinical pharmacogenomics implementation program during outpatient care--initial results of the University of Chicago "1,200 Patients Project". O'Donnell, PH., Danahey, K., Jacobs, M., et al.[2022]

Pharmacogenetics aims to optimize drug therapy by tailoring treatments to individual patients, improving both efficacy and safety, especially in oncology.

Therapeutic drug monitoring (TDM) combined with pharmacogenetic testing can help predict how a patient metabolizes drugs, allowing for personalized dosing to reduce the risk of treatment failure or toxicity.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

[Clinical application, limits and perspectives of pharmacogenetic and pharmacokinetic analysis of anticancer drugs]. Chantry, AS., Quaranta, S., Ciccolini, J., et al.[2022]

Pharmacogenomics plays a crucial role in personalized medicine by helping to tailor drug treatments to individual patients based on their genetic makeup, which can enhance therapeutic efficacy and reduce the risk of drug toxicity.

Despite the advancements in pharmacogenomics, its integration into clinical practice has been slow, but recent findings suggest that there are promising opportunities for immediate application, particularly in improving drug safety and targeted cancer therapies.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Pharmacogenomics steps toward personalized medicine. Xie, HG., Frueh, FW.[2019]

The first pharmacogenomics test approved by the FDA assesses the CYP2D6 and CYP2C19 genotypes, which can help tailor medication choices and dosages for patients, potentially improving treatment outcomes.

An interdisciplinary approach in pharmacogenomics and personalized medicine is essential for effectively integrating genomic information into clinical practice, moving towards more precise drug prescriptions based on individual genetic profiles.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Improving pharmacotherapy outcomes by pharmacogenomics: from expectation to reality? Vizirianakis, IS.[2013]

In a study involving 135 patients, pharmacogenetic (PGx) testing using a 16-gene panel identified at least one actionable variant in every participant, demonstrating its comprehensive utility in guiding medication choices.

PGx-guided recommendations led to changes in treatment for 32.4% of patients based on specific drug-gene interactions, highlighting the potential for personalized medicine to improve therapeutic outcomes.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Clinical Relevance of a 16-Gene Pharmacogenetic Panel Test for Medication Management in a Cohort of 135 Patients. Niedrig, DF., Rahmany, A., Heib, K., et al.[2021]

Pharmacogenomics helps explain why different people respond very differently to medications due to genetic variations in drug-metabolizing enzymes, transporters, and receptors.

By understanding these genetic differences, we can improve drug discovery and personalize treatments, potentially reducing the high rates of adverse drug reactions that contribute to significant health risks in the USA.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Advances in pharmacogenetics and pharmacogenomics. Vesell, ES.[2019]

Citations

1.

cpt.uchicago.edu

cpt.uchicago.edu/gps/

Genomic Prescribing System (GPS)

The Genomic Prescribing System (GPS) is a novel web-based portal used by physicians which displays interactive, patient-specific, pharmacogenomic results.

2.

withpower.com

withpower.com/trial/phase-1-2022-3e6aa

Personalized Medication Management for Multiple ...

Personalized medication management, which uses genetic information to guide drug prescriptions, aims to improve safety by reducing adverse drug reactions ( ...

3.

cpt.uchicago.edu

cpt.uchicago.edu/personalized-therapeutics-clinic/

Personalized Therapeutics Clinic

By delving into your genetic makeup, we aim to lower the risk of side effects (drug-drug interactions and drug-gene interactions) associated with multiple ...

4.

centerwatch.com

centerwatch.com/clinical-trials/listings/NCT05166694/evaluating-personalized-therapeutics-clinic-ptc-on-drug-drug-interactions-and-drug-gene-interactions

Evaluating Personalized Therapeutics Clinic (PTC) on ...

A PTC is a clinical that will test your genes to gather information about your health that may help guide prescribing advice and offer you new ...

5.

uchicagomedicine.org

uchicagomedicine.org/forefront/patient-care-articles/2017/december/personalized-therapeutics-clinic-investigates-complex-medication-issues-recommends-alternatives

Personalized therapeutics clinic investigates medication ...

When two people take the same medicine at the same dose, the results are rarely identical. But when multiple prescriptions are on the table ...

6.

pmc.ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov/articles/PMC11981433/

Genomic medicine and personalized treatment: a narrative ...

Personalized plans based on genomic data can assist in selecting the best medications and dosages, lowering adverse drug reactions and enhancing ...

7.

sciencedirect.com

sciencedirect.com/science/article/pii/S0010482523007941

A precision medicine approach to personalized prescribing ...

This work proposes an approach towards precision medicine that combines genetic and nongenetic factors to facilitate clinical decision-making.